P.025 APOLLO, a Phase 3 Study of Patisiran for the Treatment of Hereditary Transthyretin Amyloidosis (hattr): 18-Month Safety and Efficacy in Subgroup with Cardiac Involvement
Canadian journal of neurological sciences(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要